PHAT Dinamika bathi saben saham ing taun lumaku Phathom

Despite patent conflicts and pressure from insurers, Phathom Pharmaceuticals (PHAT) is maintaining its position. The annual earnings per share growth rate reflects the market consensus on yield rates, where 75.70 represents the current metric. Effective gastritis medications are strengthening the company's pricing power, while physician confidence in innovative esophagitis treatments confirms its status as a leader in the GI sector.

PHAT (Phathom Pharmaceuticals, Inc.) riwayat Wutah bathi ing taun lumaku saka 04.07.2022 nganti 14.11.2026

Rincian metrik keuangan lan pasar Phathom Pharmaceuticals (PHAT)

- rega saham lan prakiraan rega para ahli:

Rega Phathom Pharma|PHAT - Bagan rega target

- data kapitalisasi pasar:

Biji pasar Phathom|PHAT - Nilai Perusahaan

- statistik nilai buku emiten:

Nilai Akuntansi Saham Phathom Pharmaceuticals|PHAT - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku phathompharma.com|PHAT - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Utang Agregat marang Modal Phathom Pharmaceuticals|PHAT - Utang jangka dawa marang modal|Rasio tanggungan utang jangka cendhak marang modal phathompharma.com|PHAT - Utang perusahaan|Utang-utang marang nilai buku Phathom|PHAT - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Phathom Pharmaceuticals|Rasio jangkoan perantara phathompharma.com

- indikator pendapatan resik lan kelipatan nilai:

PHAT - Bathi resik perusahaan|Bathi forward Phathom Pharmaceuticals|PHAT - Pangali P/E|Pangali mangsa ngarep rega marang bathi Phathom|PHAT - Pangali PEG|Pangali EV/EBITDA Phathom|PHAT - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Phathom Pharmaceuticals|PHAT - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan phathompharma.com|PHAT - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Phathom Pharmaceuticals

- informasi babagan volume dodolan lan pendapatan:

PHAT - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan Phathom Pharma|PHAT - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phathom

Analisis dhasar perusahaan:PHAT Phathom Pharma

Phathom Pharmaceuticals' specialization in gastrointestinal drugs and the implementation of eco-friendly waste disposal standards require significant capital expenditures that impact net income. By analyzing EPS dynamics compared to the previous year, an investor assesses the percentage change in earnings per share, which reveals the actual business efficiency and determines whether the securities are overvalued relative to competitors.

Pesaing utama

TERN: Wutah bathi resik saben siji saham kanggo taun lumaku|Wutah bathi saben saham ing taun lumaku Ironwood Pharma|Curanex - Dinamika bathi saben saham ing taun lumaku|Wutah bathi ing taun lumaku IMRN|EVOK (evokepharma.com) - Tambahing bathi saben saham ing taun lumaku|Wutah bathi ing taun lumaku ENTO (Entero Therapeutics)|Wutah bathi ing taun lumaku RedHill Biopharma Ltd RDHL|PALI: Wutah bathi resik saben saham ing taun iki|Jaguar Health Corp - Wutah bathi resik saben siji saham kanggo taun lumaku|BIOR: Wutah bathi ing taun lumaku|morphictx.com - Tambahing bathi saben saham ing taun lumaku